V. Gupta

发表

Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan

I. Dokal, C. Dalley, K. Amarasinghe, 2007, Bone Marrow Transplantation.

No increased mortality from donor or recipient hepatitis B‐ and/or hepatitis C‐positive serostatus after related‐donor allogeneic hematopoietic cell transplantation

M. Aljurf, M. Horowitz, J. Wingard, 2012, Transplant infectious disease : an official journal of the Transplantation Society.

Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis

A. Roberts, M. Wadleigh, A. Tefferi, 2018, Leukemia.

Anti-leukemia effect of ex vivo expanded DNT cells from AML patients: a potential novel autologous T-cell adoptive immunotherapy

M. Minden, R. Childs, P. Dokouhaki, 2011, Leukemia.

Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?

R. Hoffman, J. Prchal, J. Mascarenhas, 2015, Bone Marrow Transplantation.

Vascular Events Associated with Alpha Interferon Therapy

M. Minden, J. Lipton, H. Messner, 2003, Leukemia & lymphoma.

Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis

S. Verstovsek, H. Sun, J. Gotlib, 2015, Leukemia.

Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma

R. Fonseca, A. Dispenzieri, R. Kyle, 2013, Leukemia.

The risk of polyomavirus BK-associated hemorrhagic cystitis after allogeneic hematopoietic SCT is associated with myeloablative conditioning, CMV viremia and severe acute GVHD

J. Lipton, J. Kuruvilla, M. Shanavas, 2014, Bone Marrow Transplantation.

What are RBC-transfusion-dependence and -independence?

T. Barbui, S. Verstovsek, R. Hoffman, 2011, Leukemia research.

Myeloablative conditioning regimens for AML allografts: 30 years later

A. Keating, H. Lazarus, Vikas Gupta, 2003, Bone Marrow Transplantation.

Marrow transplants from matched unrelated donors for aplastic anaemia using alemtuzumab, fludarabine and cyclophosphamide based conditioning

S. Ball, M. Ortín, J. Marsh, 2005, Bone Marrow Transplantation.

Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low‐dose acyclovir prophylaxis and pre‐transplant diagnosis of lymphoproliferative disorders

M. Minden, J. Lipton, J. Kuruvilla, 2008, Transplant infectious disease : an official journal of the Transplantation Society.

Intravascular Large B Cell Lymphoma with CNS Involvement Successfully Treated with High-Dose Methotrexate and High-Dose Ara-C Based CNS-Directed Chemoimmunotherapy Alternating with Anthracycline Based Chemoimmunotherapy

H. Tun, M. Alhaj Moustafa, Liuyan Jiang, 2022, Blood and lymphatic cancer : targets and therapy.

H. Tun, M. Alhaj Moustafa, Liuyan Jiang, 2022 .

Risk model incorporating donor IL6 and IFNG genotype and gastrointestinal GVHD can discriminate patients at high risk of steroid refractory acute GVHD

J. Lipton, E. Atenafu, J. Kuruvilla, 2015, Bone Marrow Transplantation.

Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group

M. Griesshammer, N. Kröger, T. Barbui, 2015, Leukemia.

Comparable outcomes post allogeneic hematopoietic cell transplant for patients with de novo or secondary acute myeloid leukemia in first remission

J. Lipton, E. Atenafu, J. Kuruvilla, 2015, Bone Marrow Transplantation.

Long-term outcome after intensive therapy with etoposide, melphalan, total body irradiation and autotransplant for acute myeloid leukemia

R. Tsang, M. Crump, A. Keating, 2004, Bone Marrow Transplantation.

A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and over

B. Leber, M. Minden, M. Moore, 2009, Leukemia.

Do quality of life or physical function at diagnosis predict short-term outcomes during intensive chemotherapy in AML?

G. Tomlinson, M. Minden, S. Alibhai, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of elderly patients with acute lymphoblastic leukemia--evidence for a benefit of imatinib in BCR-ABL positive patients.

M. Minden, R. Wells, S. Kamel‐Reid, 2005, Leukemia research.

The role of allogeneic bone marrow transplantation in adult patients below the age of 55 years with acute lymphoblastic leukemia in first complete remission: a donor vs no donor comparison

M. Minden, R. Tsang, R. Wells, 2004, Bone Marrow Transplantation.

Long-term outcomes in adult patients below the age of 55 years with acute lymphoblastic leukemia treated with chemotherapy or allogeneic BM transplant in first CR

M. Minden, J. Lipton, A. Schimmer, 2010, Bone Marrow Transplantation.

Marrow transplantation for severe aplastic anemia with significant renal impairment

J. Lipton, H. Messner, A. Gerrie, 2007, Bone Marrow Transplantation.

Large granular lymphocytosis and its impact on long-term clinical outcomes following allo-SCT

T. Panzarella, J. Lipton, J. Kuruvilla, 2013, Bone Marrow Transplantation.

A phase II study of temozolomide therapy for poor-risk patients aged ⩾60 years with acute myeloid leukemia: low levels of MGMT predict for response

M. Minden, R. Wells, S. Alibhai, 2007, Leukemia.

A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis

B. Leber, N. Kröger, J. Lipton, 2009, Bone Marrow Transplantation.

The outcome of intensive induction therapy in patients ⩾70 years with acute myeloid leukemia

M. Minden, S. Alibhai, A. Schimmer, 2007, Leukemia.

Imatinib Mesylate (Gleevec™) is a Useful Agent in the Salvage Treatment of Adults with Relapsed/refractory Philadelphia Positive Acute Leukemias

M. Minden, S. Kamel‐Reid, J. Lipton, 2003, Hematology.

Impact of intensity of conditioning therapy in patients aged 40–60 years with AML/myelodysplastic syndrome undergoing allogeneic transplantation

G. Guyatt, J. Lipton, J. Kuruvilla, 2011, Bone Marrow Transplantation.

Venous thromboembolism prevention during asparaginase-based therapy for acute lymphoblastic leukemia.

M. Minden, A. Schimmer, K. Yee, 2016, Current oncology.

Duration of first remission, hematopoietic cell transplantation-specific comorbidity index and patient age predict survival of patients with AML transplanted in second CR

J. Lipton, E. Atenafu, J. Kuruvilla, 2013, Bone Marrow Transplantation.

Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: Impact of tyrosine kinase inhibitor and minimal residual disease

M. Norkin, R. Vij, M. Aljurf, 2013, Leukemia.

Tolerance to liver allograft after allogeneic hematopoietic cell transplantation for severe aplastic anemia from the same HLA-matched sibling donor

J. Lipton, G. Therapondos, V. Gupta, 2012, Bone Marrow Transplantation.

Patient age, remission status and HCT-CI in a combined score are prognostic for patients with AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2

J. Lipton, E. Atenafu, J. Kuruvilla, 2015, Bone Marrow Transplantation.

A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: inhibition of Akt activation correlates with complete response

M. Minden, D. Hedley, S. Kamel‐Reid, 2011, Leukemia.

Graft-versus-host disease following marrow transplantation for aplastic anemia: different impact of two GVHD prevention strategies

M. Minden, S. Kamel‐Reid, J. Lipton, 2008, Bone Marrow Transplantation.

The prognostic impact of FLT3-ITD and NPM1 mutations in patients with relapsed acute myeloid leukemia and intermediate-risk cytogenetics

M. Minden, S. Kamel‐Reid, A. Schimmer, 2013, Blood Cancer Journal.

Evidence of graft-versus-Waldenstrom's macroglobulinaemia effect after allogeneic stem cell transplantation: a single centre experience

J. Lipton, J. Kuruvilla, H. Messner, 2007, Bone Marrow Transplantation.

Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning

J. Lipton, E. Atenafu, J. Kuruvilla, 2014, Bone Marrow Transplantation.

Risk stratification of organ-specific GVHD can be improved by single-nucleotide polymorphism-based risk models

H. Won, J. Lipton, J. Kuruvilla, 2014, Bone Marrow Transplantation.

PS961 PATIENTS WITH RELAPSED MIXED PHENOTYPE ACUTE LEUKEMIA HAVE SHORT REMISSION DURATION WITH RE-INDUCTION: A SINGLE CENTER EXPERIENCE

M. Minden, Steven M. Chan, A. Schimmer, 2019, HemaSphere.

Outcomes of patients with therapy-related AML/myelodysplastic syndrome (t-AML/MDS) following hematopoietic cell transplantation

J. Lipton, E. Atenafu, J. Kuruvilla, 2015, Bone Marrow Transplantation.

Relationship between neurocognitive functioning and medication management ability over the first 6 months following allogeneic stem cell transplantation

J. Lipton, S. Rourke, K. Metcalfe, 2016, Bone Marrow Transplantation.

Safety and efficacy of CYT387, a JAK-1/2 inhibitor, for the treatment of myelofibrosis.

A. Roberts, A. Tefferi, D. Caramazza, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Older age is associated with similar quality of life and physical function compared to younger age during intensive chemotherapy for acute myeloid leukemia.

G. Tomlinson, M. Minden, S. Alibhai, 2012, Leukemia research.

Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma

A. Dispenzieri, M. Gertz, M. Lacy, 2014, Leukemia.

Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF).

J. Dipersio, H. Kantarjian, S. Verstovsek, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Do quality of life or physical function at diagnosis predict short-term outcomes during intensive chemotherapy in AML?

G. Tomlinson, M. Minden, S. Alibhai, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.